TCT 2024 - TCTMD.com
Oct 27, 2024 · TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
Tirzepatide Bests Semaglutide for Weight Loss: SURMOUNT-5 …
Dec 4, 2024 · In a head-to-head tussle between two obesity drugs, tirzepatide came out on top of semaglutide for weight loss, according to topline results from the SURMOUNT-5 trial released by Eli Lilly on Wednesday.
AHA 2024 | tctmd.com
TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting the next wave of innovation in research and education that will help doctors save and improve the quality of their patients’ lives.
Semaglutide Helps in HFpEF Irrespective of Frailty, Exercise Capacity
Oct 1, 2024 · Once-weekly semaglutide (Wegovy; Novo Nordisk) improves outcomes in patients who have obesity-related heart failure with preserved ejection fraction (HFpEF) across subgroups defined by baseline 6-minute walk distance and frailty status, according to two prespecified analyses of the STEP-HFpEF program.
EARLY TAVR Breaks New Ground for Preemptive Treatment of …
Oct 28, 2024 · Disclosures. EARLY TAVR was sponsored by Edwards Lifesciences. Généreux reports consulting for and/or receiving speaking fees from Abbott Vascular, Abiomed, Boston Scientific, Caranx Medical, Cardiovascular System Inc, Edwards Lifesciences, GE Healthcare, iRhythm Technologies, Medtronic, OpSens, Pi-Cardiac, Puzzle Medical, Saranas, Shockwave, Siemens, Soundbite Medical Inc, Teleflex, and 4C ...
SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity
Nov 16, 2024 · CHICAGO, IL—Tirzepatide (Eli Lilly) significantly cut the risk of cardiovascular mortality and worsening heart failure events by nearly 40% over a median follow-up of roughly 2 years in patients with obesity and heart failure with preserved ejection (HFpEF), results of the SUMMIT trial show.
Cheaper Version of Tirzepatide for Weight Loss Now Available, …
Aug 28, 2024 · The manufacturer is selling single-dose vials of the drug via its online pharmacy at around $400 to $500 for a 4-week supply.
FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR ...
Nov 25, 2024 · Acoramidis (Attruby; BridgeBio), a drug that stabilizes transthyretin and has demonstrated benefit on cardiovascular outcomes, has been approved by the US Food and Drug Administration for the treatment of adults with transthyretin amyloid cardiomyopathy (ATTR-CM).
Micra Leadless Pacemaker Performs Well Through 5 Years
Mar 6, 2024 · Photo Credit: Adapted from Brown K. TCT 564: A new perspective: intracardiac echocardiographic guidance for the implantation of a left atrial appendage occluder device (Watchman) with a leadless pacemaker (Micra).
TCTMD’s Top 10 Most Popular Stories for October 2024
Nov 1, 2024 · Conference news filled our list this month, dominated by TCT 2024, although two EACTS stories also cracked our top 10.